Email: cspc@cspc.cn
Media
News Center
Sep. 04
2022
A Special Inspection
May 2020 saw a significant improvement in the epidemic situation in China, and CSPC Weisheng was about to have its first OU Kosher inspection since the outbreak of the epidemic.
Aug. 30
“MOXIFLOXACIN HYDROCHLORIDE AND SODIUM CHLORIDE INJECTION” OBTAINS DRUG REGISTRATION APPROVAL
The“Moxifloxacin Hydrochloride and Sodium Chloride Injection has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China, and is deemed to have passed the consistency evaluation of quality and efficacy of generic drugs.
CLASS 1 NEW DRUG “PRUSOGLIPTIN TABLETS” MEETS PREDEFINED ENDPOINTS IN THE PIVOTAL CLINICAL TRIALS
The class 1 new drug “Prusogliptin Tablets” (“DBPR108 Tablets”) of CSPC has met the predefined endpoints in two pivotal clinical trials for the treatment of type 2 diabetes.
SELECTIVE NTRK AND ROS1 DUAL INHIBITOR “SYHX2009” OBTAINS CLINICAL TRIAL APPROVAL
“SYHX2009” (the “Product”) developed by the Group has obtained approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.
Jul. 27
Congratulations on the Successful Approval and Launch of Mitoxantrone Liposome
Mitoxantrone hydrochloride liposome for injection (10ml:10mg), our key innovative product, has been launched successfully on January 11. This product is a self-developed anti-tumor nano-drug of CSPC as well as the first mitoxantrone nano-drug launched in the world
Jul. 20
CSPC advances to the 25th Place in the Pharma 1000 List
Recently, Torreya published The Pharma 1000: Top Global Pharmaceutical Company Report. The Report ranks the world's top 1,000 pharmaceutical companies by valuation and provides the latest developments of the global pharmaceutical industry in 2021. CSPC was included in the list again, ranking 25th and taking second place among the Chinese pharmaceut
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
